Longitudinal and Multimodal Radiomics Models for Head and Neck Cancer Outcome Prediction.
Cox proportional hazards
computed tomography
head and neck cancer
loco-regional control
longitudinal imaging
positron emission tomography
radiomics
survival analysis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Jan 2023
21 Jan 2023
Historique:
received:
01
12
2022
revised:
10
01
2023
accepted:
16
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
12
2
2023
Statut:
epublish
Résumé
Radiomics analysis provides a promising avenue towards the enabling of personalized radiotherapy. Most frequently, prognostic radiomics models are based on features extracted from medical images that are acquired before treatment. Here, we investigate whether combining data from multiple timepoints during treatment and from multiple imaging modalities can improve the predictive ability of radiomics models. We extracted radiomics features from computed tomography (CT) images acquired before treatment as well as two and three weeks after the start of radiochemotherapy for 55 patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Additionally, we obtained features from FDG-PET images taken before treatment and three weeks after the start of therapy. Cox proportional hazards models were then built based on features of the different image modalities, treatment timepoints, and combinations thereof using two different feature selection methods in a five-fold cross-validation approach. Based on the cross-validation results, feature signatures were derived and their performance was independently validated. Discrimination regarding loco-regional control was assessed by the concordance index (C-index) and log-rank tests were performed to assess risk stratification. The best prognostic performance was obtained for timepoints during treatment for all modalities. Overall, CT was the best discriminating modality with an independent validation C-index of 0.78 for week two and weeks two and three combined. However, none of these models achieved statistically significant patient stratification. Models based on FDG-PET features from week three provided both satisfactory discrimination (C-index = 0.61 and 0.64) and statistically significant stratification (p=0.044 and p<0.001), but produced highly imbalanced risk groups. After independent validation on larger datasets, the value of (multimodal) radiomics models combining several imaging timepoints should be prospectively assessed for personalized treatment strategies.
Identifiants
pubmed: 36765628
pii: cancers15030673
doi: 10.3390/cancers15030673
pmc: PMC9913206
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
NPJ Precis Oncol. 2019 Oct 4;3:25
pubmed: 31602401
Sci Rep. 2017 Oct 30;7(1):14331
pubmed: 29085044
Radiother Oncol. 2017 Sep;124(3):533-540
pubmed: 28843726
Nat Rev Cancer. 2016 Apr;16(4):234-49
pubmed: 27009394
Eur Radiol. 2021 Mar;31(3):1460-1470
pubmed: 32909055
Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2656-2672
pubmed: 31214791
Sci Rep. 2017 Apr 3;7(1):588
pubmed: 28373718
Radiother Oncol. 2019 Jan;130:10-17
pubmed: 30087056
Med Phys. 2020 Jun;47(5):e185-e202
pubmed: 32418336
Sci Rep. 2020 Sep 24;10(1):15625
pubmed: 32973220
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):942-952
pubmed: 30940529
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929
Sci Rep. 2019 Jan 24;9(1):614
pubmed: 30679599
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Radiother Oncol. 2019 Jul;136:78-85
pubmed: 31015133
Radiother Oncol. 2017 Dec;125(3):385-391
pubmed: 29122358
Radiother Oncol. 2005 Aug;76(2):151-6
pubmed: 16026875
Nat Rev Cancer. 2011 Jan;11(1):9-22
pubmed: 21160525
Front Oncol. 2015 Dec 03;5:272
pubmed: 26697407
Cancers (Basel). 2022 Feb 26;14(5):
pubmed: 35267535
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Neuroimage Clin. 2018;20:1070-1077
pubmed: 30366279
Adv Radiat Oncol. 2019 Jan 10;4(2):390-400
pubmed: 31011685
Phys Med. 2020 Dec;80:84-91
pubmed: 33137623
Acta Oncol. 2021 Sep;60(9):1192-1200
pubmed: 34038324
Radiother Oncol. 2012 Oct;105(1):21-8
pubmed: 23022173
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1107-1116
pubmed: 29506884
PLoS One. 2019 Sep 19;14(9):e0222509
pubmed: 31536526
Comput Methods Programs Biomed. 2022 Jul;222:106948
pubmed: 35752119
Radiother Oncol. 2016 Dec;121(3):364-373
pubmed: 27913065
Head Neck Tumor Segm Chall (2021). 2022;13209:287-299
pubmed: 35399868
Sci Rep. 2017 Aug 31;7(1):10117
pubmed: 28860628
Front Oncol. 2020 May 12;10:618
pubmed: 32477932
Sci Rep. 2021 Mar 19;11(1):6418
pubmed: 33742070
Acta Oncol. 2022 Jan;61(1):73-80
pubmed: 34632924
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
Sci Rep. 2017 Oct 16;7(1):13206
pubmed: 29038455
Front Oncol. 2022 Sep 23;12:936040
pubmed: 36212477
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1205-13
pubmed: 21489709
Eur Radiol. 2020 Nov;30(11):6311-6321
pubmed: 32500196
IEEE Trans Pattern Anal Mach Intell. 2005 Aug;27(8):1226-38
pubmed: 16119262